Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is in the spotlight today after unveiling topline results from its pivotal Phase 3 RISE UP trial of mitapivat (Pyrukynd) in sickle cell disease (SCD) — data that are being widely described as “mixed” and